Kunshan Xinyunda Biotechnology

Kunshan Xinyunda Biotechnology is a clinical-stage biopharmaceutical company based in Kunshan, China, dedicated to the discovery and development of novel small molecule therapeutics. The company primarily focuses on the field of targeted protein degradation, utilizing its proprietary Proteolysis-targeting chimera (PROTAC) platform to address previously undruggable targets. Its lead program, XYD-001, is an androgen receptor degrader currently in clinical development for metastatic castration-resistant prostate cancer. Xinyunda's research strategy emphasizes precision medicine and the treatment of solid tumors with high unmet medical needs. The company is supported by regional investment funds and maintains a strong R&D presence in the Jiangsu biotechnology corridor.